ARTHROCARE ARTHROWANDS

K082323 · Arthrocare Corp. · GEI · Aug 28, 2008 · General, Plastic Surgery

Device Facts

• Record ID: K082323
• Device Name: ARTHROCARE ARTHROWANDS
• Applicant: Arthrocare Corp.
• Product Code: GEI · General, Plastic Surgery
• Decision Date: Aug 28, 2008
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 878.4400
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The ArthroCare ArthroWands are indicated for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures: (Table of procedures including ACL/PCL, acromioplasty, articular cartilage, bursectomy, chondroplasty, facia, ligament, notchplasty, scar tissue, soft tissue, subacromial decompression, synovectomy, tendon, acetabular labrum, articular labrum, capsule, capsular release, cartilage flaps, cysts, discoid meniscus, frozen shoulder release, glenoidale labrum, lateral release, loose bodies, meniscal cystectomy, meniscectomy, plica removal, synovial membrane, triangular fibrocartilage (TFCC), villusectomy, carpal ligaments, glenohumeral capsule, medial retinaculum, and rotator cuff across various joints including ankle, elbow, hip, knee, shoulder, and wrist).

Device Story

ArthroCare ArthroWands are bipolar, single-use, high-frequency electrosurgical devices. Used in arthroscopic and orthopedic procedures for soft tissue resection, ablation, coagulation, and hemostasis. Operated by surgeons in clinical settings. Device delivers high-frequency energy to target tissue; enables precise cutting and coagulation. Benefits include efficient tissue management and bleeding control during minimally invasive joint surgeries.

Clinical Evidence

No clinical data provided; substantial equivalence based on technological characteristics and intended use.

Technological Characteristics

Bipolar, high-frequency electrosurgical device. Single-use. Materials modified from predicate. Energy source: high-frequency electrosurgical generator. Sterilization: parameters remain consistent with predicate.

Indications for Use

Indicated for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures involving the ankle, elbow, hip, knee, shoulder, and wrist.

Regulatory Classification

Identification

An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.

Predicate Devices

• ArthroCare ArthroWands (K072865)

Submission Summary (Full Text)

{0}------------------------------------------------

K082323

## 510(k) Summary

# ArthroCare Corporation ArthroCare ArthroWands

AUG 2 8 2008

## General Information

Submitter Name/Address:

Establishment Registration Number: Contact Person:

Date Prepared:

Device Description

Trade Name:

Generic/Common Name:

Classification Name:

ArthroCare Corporation 680 Vaqueros Avenue Sunnyvale, CA 94085-3523

2951580

Valerie Defiesta-Ng Director, Regulatory Affairs

August 11, 2008

ArthroCare® ArthroWands®

Electrosurgical Device and Accessories

Electrosurgical Cutting and Coagulation Device and Accessories (21 CFR 878.4400)

Predicate Devices

ArthroCare® ArthroWands®

K072865

#### Product Description

The ArthroCare ArthroWands are bipolar, single use, high frequency electrosurgical devices designed for specific indications in arthroscopic and orthopedic procedures.

{1}------------------------------------------------

## Intended Uses

The ArthroCare ArthroWands are indicated for resection, ablation, and coagulation of The Tital Ocale TimboWands are ressels in arthroscopic and orthopedic procedures:

| Arthroscopic and Orthopedic Procedures | Joint Specific or All<br>Joints (ankle, elbow,<br>hip, knee, shoulder, and<br>wrist) |
|----------------------------------------|--------------------------------------------------------------------------------------|
| Ablation and Debridement | |
| • ACL/PCL | Knee |
| • Acromioplasty | Shoulder |
| • Articular Cartilage | All Joints |
| • Bursectomy | All Joints |
| • Chondroplasty | All Joints |
| • Facia | All Joints |
| • Ligament | All Joints |
| • Notchplasty | Knee |
| • Scar Tissue | All Joints |
| • Soft Tissue | All Joints |
| • Subacromial Decompression | Shoulder |
| • Synovectomy | All Joints |
| • Tendon | All Joints |
| Excision and Resection | |
| • Acetabular Labrum | Hip |
| • Articular Labrum | All Joints |
| • Capsule | All Joints |
| • Capsular Release | Knee |
| • Cartilage Flaps | Knee |
| • Cysts | All Joints |
| • Discoid Meniscus | Knee |
| • Frozen Shoulder Release | Shoulder |
| • Glenoidale Labrum | Shoulder |
| • Lateral Release | Knee |
| • Ligament | All Joints |
| • Loose Bodies | All Joints |
| • Meniscal Cystectomy | Knee |
| • Meniscectomy | Knee |

{2}------------------------------------------------

| Arthroscopic and Orthopedic Procedures | Joint Specific or All<br>Joints (ankle, elbow,<br>hip, knee, shoulder, and<br>wrist) |
|----------------------------------------|--------------------------------------------------------------------------------------|
| • Plica Removal | All Joints |
| • Scar Tissue | All Joints |
| • Soft Tissue | All Joints |
| • Synovial Membrane | All Joints |
| • Tendon | All Joints |
| • Triangular Fibrocartilage (TFCC) | Wrist |
| • Villusectomy | Knee |
| Coagulation | |
| • ACL/PCL | Knee |
| • Articular Cartilage | All Joints |
| • Carpal Ligaments | Wrist |
| • Glenohumeral Capsule | Shoulder |
| • Ligament | All Joints |
| • Medial Retinaculum | Knee |
| • Rotator Cuff | Shoulder |
| • Tendon | All Joints |
| • Wrist Tendons | Wrist |

## Substantial Equivalence

This Special 510(k) proposes modifications in the materials specification and labeling for the ArthroCare ArthroWands, which were previously cleared in K072865 (October 23, 2007). The indications for use, technology, principle of operation, and sterilization parameters of the ArthroCare ArthroWands remain the same as in the predicate cleared 510(k)s.

## Summary of Safety and Effectiveness

The modified ArthroCare ArthroWands, as described in this Special 510(k), are substantially equivalent to the predicate device. The proposed modifications in the materials and labeling are not substantial changes or modifications, and do not significantly affect the safety or efficacy of the devices.

{3}------------------------------------------------

Image /page/3/Picture/2 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with three tail feathers, representing the department's commitment to health, human services, and well-being. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES. USA" is arranged in a circular pattern around the eagle.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Arthrocare Corporation % Ms. Valerie Defiesta-Ng Director, Regulatory Affairs 680 Vaqueros Avenue Sunnyvale, California 94085-3523

AUG 2 8 2008

Re: K082323

Trade/Device Name: ArthoCare® ArthroWands® Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical cutting and coagulation device and accessories Regulatory Class: II Product Code: GEI Dated: August 11, 2008 Received: August 14, 2008

Dear Ms. Defiesta-Ng:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set

{4}------------------------------------------------

Page 2 - Ms. Valerie Defiesta-Ng

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at [phone]. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at [phone]. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N Millman

Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

**Indications for Use Statement**

к_082323 510(k) Number:

ArthroCare® ArthroWands® Device Name

Indications for Use:

(Division Sign-Off) Division of General, Restorative, and Neurological Devices

**510(k) Number** K082323

The ArthroCare ArthroWands are indicated for resection, ablation, and coagulation of soft tissue and hemostasis of blood vessels in arthroscopic and orthopedic procedures:

| Arthroscopic and Orthopedic Procedures | Joint Specific or All Joints (ankle, elbow, hip, knee, shoulder, and wrist) | |
|----------------------------------------|-----------------------------------------------------------------------------|------------|
| Ablation and Debridement | | |
| ● | ACL/PCL | Knee |
| ● | Acromioplasty | Shoulder |
| ● | Articular Cartilage | All Joints |
| ● | Bursectomy | All Joints |
| ● | Chondroplasty | All Joints |
| ● | Facia | All Joints |
| ● | Ligament | All Joints |
| ● | Notchplasty | Knee |
| ● | Scar Tissue | All Joints |
| ● | Soft Tissue | All Joints |
| ● | Subacromial Decompression | Shoulder |
| ● | Synovectomy | All Joints |
| ● | Tendon | All Joints |
| Excision and Resection | | |
| ● | Acetabular Labrum | Hip |
| ● | Articular Labrum | All Joints |
| ● | Capsule | All Joints |
| ● | Capsular Release | Knee |
| ● | Cartilage Flaps | Knee |
| ● | Cysts | All Joints |
| ● | Discoid Meniscus | Knee |
| ● | Frozen Shoulder Release | Shoulder |
| ● | Glenoidale Labrum | Shoulder |
| ● | Lateral Release | Knee |
| ● | Ligament | All Joints |
| ● | Loose Bodies | All Joints |
| ● | Meniscal Cystectomy | Knee |
| ● | Meniscectomy | Knee |

$$x$$

1000

{6}------------------------------------------------

| Arthroscopic and Orthopedic Procedures | Joint Specific or All<br>Joints (ankle, elbow,<br>hip, knee, shoulder, and<br>wrist) |
|----------------------------------------|--------------------------------------------------------------------------------------|
| • Plica Removal | All Joints |
| • Scar Tissue | All Joints |
| • Soft Tissue | All Joints |
| • Synovial Membrane | All Joints |
| • Tendon | All Joints |
| • Triangular Fibrocartilage (TFCC) | Wrist |
| • Villusectomy | Knee |
| Coagulation | |
| • ACL/PCL | Knee |
| • Articular Cartilage | All Joints |
| • Carpal Ligaments | Wrist |
| • Glenohumeral Capsule | Shoulder |
| • Ligament | All Joints |
| • Medial Retinaculum | Knee |
| • Rotator Cuff | Shoulder |
| • Tendon | All Joints |

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR X

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE)

Mark A. Milliman

(Division Sign iorative, Div

ಚಿ

france fr

K0823